Business Context and Reporting Period
This Form 8-K was filed by PluriStem Therapeutics Inc. on June 20, 2017. The registrant is a Nevada corporation headquartered in Haifa, Israel, operating in the biotechnology sector.
Key Financial Metrics
The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a corporate event regarding a terminated investment agreement.
Material Changes
On June 20, 2017, PluriStem Therapeutics Inc. and Innovative Medical Management Co. Ltd. (Innovative) terminated their plan to execute definitive agreements for a proposed investment of $30,000,000 by Innovative. The termination was caused by a recently adopted Chinese policy restricting outbound investments by Chinese companies.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance or management commentary on future operations. The primary risk disclosed is the regulatory environment in China, which directly prevented the closing of the $30 million investment.
Investor Verification Checklist
- Verify the specific details of the Chinese outbound investment policy cited as the cause for termination.
- Confirm the current cash position of PluriStem Therapeutics Inc. following the loss of the $30 million funding source.
- Assess whether the company has alternative financing plans to replace the terminated investment.
- Review subsequent filings for any updates on the relationship with Innovative Medical Management Co. Ltd.